消除「不良记忆」:逆转异常突触可塑性作为神经与精神障碍的治疗策略
本文综述多巴胺调控皮质纹状体直接与间接通路可塑性的机制,提出预防或逆转适应不良的突触强度、消除异常「记忆」可能成为多种神经与精神障碍的疾病修饰治疗策略。文章汇总帕金森病、药物诱发性帕金森综合征、左旋多巴诱导的运动障碍、强迫症、物质使用障碍和抑郁症及动物模型证据,并讨论cAMP通路、突触可塑性蛋白、新蛋白合成通路及RNA结合蛋白与表观转录组机制等潜在分子靶点。
要点
- 多巴胺失调可导致适应不良反应被选择、适当反应被抑制,形成异常突触「记忆」。
- 预防或逆转异常突触强度可能是多种神经与精神障碍的疾病修饰治疗策略。
- 药物联合行为治疗或深脑刺激可能改变特定神经环路, correcting异常可塑性或带来持久疗效。
核心结论
- 预防或逆转适应不良的突触强度、消除异常「记忆」可能是许多神经与精神障碍的疾病修饰治疗策略。
研究设计与样本
- 本文为综述,汇总帕金森病、药物诱发性帕金森综合征、左旋多巴诱导的运动障碍、强迫症、物质使用障碍和抑郁症及动物疾病模型的研究证据。
主要发现
- 正常条件下皮质纹状体可塑性机制使最适当反应被选择而其他反应被抑制。
- 多巴胺释放或信号缺乏时,这些机制可以经验依赖和任务特异的方式导致适应不良反应被选择和/或适当反应被抑制。
- 来自上述疾病及动物模型的研究提示 translational neuroscience 中一个新兴主题和治疗开发的 promising 新方向。
- 作者提出药物联合行为治疗或深脑刺激可能对特定神经环路产生期望的改变。
- 若成功,纠正异常突触可塑性的一个重要优势是治疗结束后仍可有持久疗效。
关键数值与推荐
- 潜在分子靶点包括cAMP通路、参与突触可塑性的蛋白以及参与新蛋白合成的通路。
- 特别强调RNA结合蛋白和表观转录组机制,因其可快速、同时局部改变多种蛋白合成。
临床怎么用
- 作者提出联合药物与行为治疗或深脑刺激可能对特定神经环路产生期望的改变。
- 作者提出纠正异常突触可塑性若成功,可能带来治疗结束后仍持久的疗效。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Dopamine modulates corticostriatal plasticity in both the direct and indirect pathways of the cortico-striato-thalamo-cortical (CSTC) loops. These gradual changes in corticostriatal synaptic strengths produce long-lasting changes in behavioral responses. Under normal conditions, these mechanisms enable the selection of the most appropriate responses while inhibiting others. However, under dysregulated dopamine conditions, including a lack of dopamine release or dopamine signaling, these mechanisms could lead to the selection of maladaptive responses and/or the inhibition of appropriate responses in an experience-dependent and task-specific manner. In this review, we propose that preventing or reversing such maladaptive synaptic strengths and erasing such aberrant "memories" could be a disease-modifying therapeutic strategy for many neurological and psychiatric disorders. We review evidence from Parkinson's disease, drug-induced parkinsonism, L-DOPA-induced dyskinesia, obsessive-compulsive disorder, substance use disorders, and depression as well as research findings on animal disease models. Altogether, these studies allude to an emerging theme in translational neuroscience and promising new directions for therapy development. Specifically, we propose that combining pharmacotherapy with behavioral therapy or with deep brain stimulation (DBS) could potentially cause desired changes in specific neural circuits. If successful, one important advantage of correcting aberrant synaptic plasticity is long-lasting therapeutic effects even after treatment has ended. We will also discuss the potential molecular targets for these therapeutic approaches, including the cAMP pathway, proteins involved in synaptic plasticity as well as pathways involved in new protein synthesis. We place special emphasis on RNA binding proteins and epitranscriptomic mechanisms, as they represent a new frontier with the distinct advantage of rapidly and simultaneously altering the synthesis of many proteins locally.
引用
- Shi Z, Wen K, Sammudin NH, et al. Erasing "bad memories": reversing aberrant synaptic plasticity as therapy for neurological and psychiatric disorders. Mol Psychiatry. 2025. PMID: 40210977. doi:10.1038/s41380-025-03013-0
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。